XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and other preclinical product candidates, such as interleukin 2, a therapy for metastatic melanoma and renal cell carcinoma, as well as anti-parathyroid receptor to address unmet medical needs. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration and licensing agreements with Novartis AG; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone510-204-7200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$52.69 million
Profitability
Miscellaneous
Employees12
OptionableNot Optionable
XOMA (NASDAQ:XOMA) Frequently Asked Questions
What is XOMA's stock symbol?
XOMA trades on the NASDAQ under the ticker symbol "XOMA."
How were XOMA's earnings last quarter?
XOMA Corp (NASDAQ:XOMA) announced its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.40. The biotechnology company earned $0.90 million during the quarter, compared to analysts' expectations of $0.83 million. XOMA had a negative net margin of 129.85% and a negative return on equity of 267.64%. View XOMA's Earnings History.
When is XOMA's next earnings date?
What price target have analysts set for XOMA?
3 brokerages have issued twelve-month price targets for XOMA's stock. Their predictions range from $16.26 to $36.00. On average, they anticipate XOMA's share price to reach $28.42 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price. View Analyst Price Targets for XOMA.
What is the consensus analysts' recommendation for XOMA?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XOMA.
What are Wall Street analysts saying about XOMA stock?
Here are some recent quotes from research analysts about XOMA stock:
- 1. HC Wainwright analysts commented, "Valuation disconnect continues even when considering a limited set of current assets. Regarding our valuation of XOMA we believe that the current share price is currently disconnected from the underlying value of even just its opportunity from Novartis (NVS; not rated) partnered assets, led by canakinumab (Ilaris)." (9/21/2018)
- 2. According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (8/11/2018)
Has XOMA been receiving favorable news coverage?
News articles about XOMA stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. XOMA earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are some of XOMA's key competitors?
Some companies that are related to XOMA include Forty Seven (FTSV), Corium International (CORI), Theratechnologies (THERF), Obseva (OBSV), ZEALAND PHARMA/S (ZEAL), Odonate Therapeutics (ODT), Cytokinetics (CYTK), Aptorum Group (APM), Five Prime Therapeutics (FPRX), Innate Pharma (IPHYF), Progenics Pharmaceuticals (PGNX), Osmotica Pharmaceuticals (OSMT), Beyondspring (BYSI), OvaScience (OVAS) and Rigel Pharmaceuticals (RIGL).
Who are XOMA's key executives?
XOMA's management team includes the folowing people:
- Mr. James R. Neal, CEO & Director (Age 63)
- Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 45)
- Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 43)
- Dr. Deepshikha Datta, Chief Bus. Officer
Who are XOMA's major shareholders?
XOMA's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.06%), Opaleye Management Inc. (4.77%), Fosun International Ltd (3.77%), Geode Capital Management LLC (1.00%), Northern Trust Corp (1.00%) and Bank of New York Mellon Corp (0.72%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, John Varian, Ness W Denman Van, Thomas M Burns and Value Fund L P Biotechnology. View Institutional Ownership Trends for XOMA.
Which institutional investors are selling XOMA stock?
XOMA stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Dimensional Fund Advisors LP, Geode Capital Management LLC and ClariVest Asset Management LLC. Company insiders that have sold XOMA company stock in the last year include James R Neal, Ness W Denman Van and Thomas M Burns. View Insider Buying and Selling for XOMA.
Which institutional investors are buying XOMA stock?
XOMA stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd, Opaleye Management Inc., BlackRock Inc., Chicago Equity Partners LLC, Northern Trust Corp, Bank of New York Mellon Corp, Two Sigma Advisers LP and Macquarie Group Ltd.. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal and Value Fund L P Biotechnology. View Insider Buying and Selling for XOMA.
How do I buy shares of XOMA?
Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is XOMA's stock price today?
One share of XOMA stock can currently be purchased for approximately $14.21.
How big of a company is XOMA?
XOMA has a market capitalization of $119.19 million and generates $52.69 million in revenue each year. The biotechnology company earns $14.59 million in net income (profit) each year or $0.98 on an earnings per share basis. XOMA employs 12 workers across the globe.
What is XOMA's official website?
How can I contact XOMA?
XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]
MarketBeat Community Rating for XOMA (NASDAQ XOMA)
MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
